Chronic Conditions Warehouse Virtual Research Data Center

CODEBOOK: Medicare Oncology Care Model Files

MAY 2024 | VERSION 1.0
# Revision Log

<table>
<thead>
<tr>
<th>Date</th>
<th>Changed by</th>
<th>Revisions</th>
<th>Version</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2024</td>
<td>K. Schneider</td>
<td>Initial release of codebook</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Tips on Navigating the Codebook

This document is a detailed codebook that describes each variable in the Medicare Oncology Care Model (OCM) research files. Because the files have many variables, the CCW team has included several ways for users to quickly find the information they need:

- A complete listing of all variables in the files, in alphabetical order based on their SAS variable names
- Individual entries for each variable that contain a short description of the variable, the possible values for the variable, and, in many cases, notes that discuss how the variable was constructed and should be used

The CCW team has included hyperlinks throughout the codebook to make it easier for analysts to navigate between the table of contents and the detailed entries for the individual variables:

- Clicking on any variable name in the Table of Contents takes you to the detailed description for that variable
- From the detailed description for any individual variable, clicking on the ^Back to TOC^ link after each variable description takes you back to the Table of Contents
**Table of Contents**

This section of the codebook contains a list of all variables in alphabetical order based on the SAS variable name.

**Quick links:**  
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

<table>
<thead>
<tr>
<th>Variable Details</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AJCC_EDITION</td>
<td>1</td>
</tr>
<tr>
<td>BENE_ID</td>
<td>2</td>
</tr>
<tr>
<td>CNCR_TYPE_ASGNED</td>
<td>3</td>
</tr>
<tr>
<td>CNCR_TYPE_RPTD</td>
<td>4</td>
</tr>
<tr>
<td>CRNT_CLNCL_STUS</td>
<td>5</td>
</tr>
<tr>
<td>CRNT_CLNCL_STUS_DT</td>
<td>6</td>
</tr>
<tr>
<td>DOB</td>
<td>7</td>
</tr>
<tr>
<td>DOD</td>
<td>8</td>
</tr>
<tr>
<td>EPSD_BGN_DT</td>
<td>9</td>
</tr>
<tr>
<td>EPSD_END_DT</td>
<td>10</td>
</tr>
<tr>
<td>ESTROGEN_RECEPTOR</td>
<td>11</td>
</tr>
<tr>
<td>HER2_AMPLIFICATION</td>
<td>12</td>
</tr>
<tr>
<td>HISTOLOGY</td>
<td>13</td>
</tr>
<tr>
<td>ICD10_CNCR_DGNS_CD_RPTD</td>
<td>14</td>
</tr>
<tr>
<td>INITL_DGNS_DT</td>
<td>15</td>
</tr>
<tr>
<td>METASTASIS</td>
<td>16</td>
</tr>
<tr>
<td>NODAL_DISEASE</td>
<td>18</td>
</tr>
<tr>
<td>OCM_PRCTC_ID</td>
<td>20</td>
</tr>
<tr>
<td>PRFMNC_PRD</td>
<td>21</td>
</tr>
<tr>
<td>PRMRY_TUMOR</td>
<td>22</td>
</tr>
<tr>
<td>PROGESTERONE_RECEPTOR</td>
<td>25</td>
</tr>
<tr>
<td>RPTD_TO_RGSTRY</td>
<td>26</td>
</tr>
<tr>
<td>SEX</td>
<td>27</td>
</tr>
</tbody>
</table>
Variable Details

This section of the codebook contains one entry for each variable in the Medicare Oncology Care Model files. Each entry contains variable details to facilitate understanding and use of the variables.

**AJCC_EDITION**

**LABEL:** AJCC Cancer Staging Edition

**DESCRIPTION:** The edition of the American Joint Committee on Cancer (AJCC) Cancer Staging manual used to describe the patient’s cancer stage.

**SHORT NAME:** AJCC_EDITION

**LONG NAME:** AJCC_EDITION

**TYPE:** CHAR

**LENGTH:** 3

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:**
- 7th
- 8th
- Null/missing = OCM participant did not report the staging data or it was invalid (reference details in the RPTD_TO_RGSTRY codebook entry)

**COMMENT:** For any initial diagnosis date (INITL_DGNS_DT) after 1/1/2018, this variable indicates whether the AJCC 7th edition or the AJCC 8th Edition was reported. AJCC 7th Edition is effective for cancer patients diagnosed through 12/31/2017; AJCC 8th Edition is effective for cancer patients diagnosed on or after 1/1/2018. To support participants that did not have AJCC 8th Edition staging available, the OCM Data Registry accepted either AJCC 7th Edition or AJCC 8th Edition staging values for cancer patients diagnosed on or after 1/1/2018.
<table>
<thead>
<tr>
<th><strong>BENE_ID</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LABEL:</strong></td>
</tr>
<tr>
<td><strong>DESCRIPTION:</strong></td>
</tr>
<tr>
<td><strong>SHORT NAME:</strong></td>
</tr>
<tr>
<td><strong>LONG NAME:</strong></td>
</tr>
<tr>
<td><strong>TYPE:</strong></td>
</tr>
<tr>
<td><strong>LENGTH:</strong></td>
</tr>
</tbody>
</table>
| **FILE(S):** | Clinical and staging  
Current clinical status |
| **SOURCE:** | CCW |
| **VALUES:** | — |
| **COMMENT:** | — |
**CNCR_TYPE_ASGNED**

**LABEL:** OCM-Assigned Cancer Type

**DESCRIPTION:** OCM-assigned cancer type.

**SHORT NAME:** CNCR_TYPE_ASGNED

**LONG NAME:** CNCR_TYPE_ASGNED

**TYPE:** CHAR

**LENGTH:** 35

**FILE(S):** Clinical and staging

**SOURCE:** CMS Oncology Care Model data

**VALUES:**
- Acute Leukemia
- Anal Cancer
- Bladder Cancer
- Breast Cancer
- CNS Tumor
- Chronic Leukemia
- Endocrine Tumor
- Female GU Cancer other than Ovary
- Gastro/Esophageal Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- MDS
- Malignant Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Small Intestine/Colorectal Cancer

**COMMENT:** OCM classified each episode by cancer type (e.g., prostate, lymphoma, breast). Cancer type was defined using the plurality of cancer diagnoses on qualifying evaluation and management (E&M) provider visits in the carrier file that occurred during the episode. The cancer type is used in categorizing episodes for reporting, monitoring, and risk adjustment purposes.
**CNCR_TYPE_RPTD**

**LABEL:** Participant-Reported Cancer Type

**DESCRIPTION:** Participant-reported cancer type.

**SHORT NAME:** CNCR_TYPE_RPTD

**LONG NAME:** CNCR_TYPE_RPTD

**TYPE:** CHAR

**LENGTH:** 35

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:**
- Acute Leukemia
- Anal Cancer
- Bladder Cancer
- Breast Cancer
- CNS Tumor
- Chronic Leukemia
- Endocrine Tumor
- Female GU Cancer other than Ovary
- Gastro/Esophageal Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- MDS
- Malignant Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Small Intestine/Colorectal Cancer

Null/missing = cancer type was not reported by OCM participant, or it was invalid (reference details in the RPTD_TO_RGSTRY codebook entry)

**COMMENT:** —
### CRNT_CLNCL_STUS

**LABEL:** Current Clinical Status  
**DESCRIPTION:** Current clinical status.  
**SHORT NAME:** CRNT_CLNCL_STUS  
**LONG NAME:** CRNT_CLNCL_STUS  
**TYPE:** CHAR  
**LENGTH:** 45  
**FILE(S):** Current clinical status  
**SOURCE:** Oncology Care Model Data Registry  

<table>
<thead>
<tr>
<th>Value</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deceased</td>
<td>Patient is deceased</td>
</tr>
<tr>
<td>Initial diagnosis</td>
<td>Treatment of the disease has started, and the disease has not been re-evaluated since treatment began</td>
</tr>
<tr>
<td>Local or regional recurrence/Relapse</td>
<td>Recurrence is the local or regional return of a solid tumor cancer after a clinically disease-free interval. Relapse is the return of a leukemia, lymphoma, or other hematopoietic malignancy that was not previously clinically apparent or symptomatic</td>
</tr>
<tr>
<td>Metastasis</td>
<td>Evidence of cancer in a site other than the primary tumor site that was not present at initial diagnosis or initial relapse</td>
</tr>
<tr>
<td>No evidence of disease/Remission</td>
<td>When radiological examinations or complete surgical resection of tumor with negative margins show no evidence of cancer in a patient who is being or has been treated for cancer (including a previous recurrence/relapse); or there is no morphological evidence of leukemia</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Cancer continues to grow or spread since initial diagnosis.</td>
</tr>
<tr>
<td>Recurrent or progressive disease</td>
<td>Defined as &quot;Local or Regional Recurrence/Relapse&quot; or &quot;Progressive Disease&quot; as above. This status was only available to report prior to July 1, 2017, and will only appear for patients whose episodes had not yet begun</td>
</tr>
<tr>
<td>Responding</td>
<td>Cancer is decreasing in extent or severity in response to treatment</td>
</tr>
<tr>
<td>Stable disease</td>
<td>Cancer is neither decreasing nor increasing in extent or severity</td>
</tr>
<tr>
<td>Stable, Responding, or No Evidence of Disease</td>
<td>Defined as &quot;Stable Disease,&quot; &quot;Responding,&quot; or &quot;No Evidence of Disease/Remission&quot; as above. This status was only available to report prior to July 1, 2017, and will only appear for patients whose episodes had not yet begun</td>
</tr>
</tbody>
</table>

**COMMENT:** Participants were required to enter current clinical status at least one time during each 6-month episode, and were expected to update the current clinical status if changes occurred. When there was documentation to support a current clinical status value of “Metastasis” during the episode, practices were instructed to prioritize reporting this value over other current clinical statuses that were documented during the episode, if they only going to report one status during the episode. Current clinical status may not have been reported for every episode.
**CRNT_CLNCL_STUS_DT**

**LABEL:** Current Clinical Status Date

**DESCRIPTION:** The date the current clinical status (variable called CRNT_CLNCL_STUS) was reported.

**SHORT NAME:** CRNT_CLNCL_STUS_DT

**LONG NAME:** CRNT_CLNCL_STUS_DT

**TYPE:** DATE

**LENGTH:** 8

**FILE(S):** Current Clinical Status

**SOURCE:** Oncology Care Model Data Registry

**VALUES:** Ex — 08/22/2019

**COMMENT:** Formatted as MMDDYY10 in SAS.

Current clinical status may not have been entered for every episode. Current clinical status date is not available for episodes occurring in performance period 3 (PRFMNC_PRD =3).

[^ Back to TOC ^]
DOB

LABEL: Beneficiary Date of Birth
DESCRIPTION: Beneficiary date of birth.
SHORT NAME: DOB
LONG NAME: DOB
TYPE: DATE
LENGTH: 8
FILE(S): Clinical and staging
SOURCE: CCW Master Beneficiary Summary File (MBSF)
VALUES: Ex — 10/12/1945
COMMENT: The CMS Oncology Care Model team obtained this information from the MBSF. Formatted as MMDDYY10 in SAS

^ Back to TOC ^
**DOD**

**LABEL:** Beneficiary Date of Death

**DESCRIPTION:** Beneficiary date of death.

**SHORT NAME:** DOD

**LONG NAME:** DOD

**TYPE:** DATE

**LENGTH:** 8

**FILE(S):** Clinical and staging

**SOURCE:** CCW Master Beneficiary Summary File (MBSF)

**VALUES:** Ex — 10/12/2020

**COMMENT:** The CMS Oncology Care Model team obtained this information from the MBSF. Formatted as MMDDYY10 in SAS
**EPSD_BGN_DT**

**LABEL:** Episode Beginning Date

**DESCRIPTION:** Episode beginning date.

**SHORT NAME:** EPSD_BGN_DT

**LONG NAME:** EPSD_BGN_DT

**TYPE:** DATE

**LENGTH:** 8

**FILE(S):** Clinical and staging

**SOURCE:** CMS Oncology Care Model data

**VALUES:** Ex — 10/12/2018

**COMMENT:** Formatted as MMDDYY10 in SAS

In OCM, episodes were initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim. Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months; the ending date of the episode is the variable EPSD_END_DT. Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode.
**EPSD_END_DT**

**LABEL:** Episode Ending Date

**DESCRIPTION:** Episode ending date.

**SHORT NAME:** EPSD_END_DT

**LONG NAME:** EPSD_END_DT

**TYPE:** DATE

**LENGTH:** 8

**FILE(S):** Clinical and staging

**SOURCE:** CMS Oncology Care Model data

**VALUES:** Ex — 04/12/2019

**COMMENT:** Formatted as MMDDYY10 in SAS

In OCM, episodes were initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim (variable called EPSD_BGN_DT). Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months; the ending date of the episode is this variable (EPSD_END_DT). Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode.

^ Back to TOC ^
**ESTROGEN_RECEPTOR**

**LABEL:** Breast Cancer Estrogen Receptor  
**DESCRIPTION:** Breast cancer estrogen receptor.  
**SHORT NAME:** ESTROGEN_RECEPTOR  
**LONG NAME:** ESTROGEN_RECEPTOR  
**TYPE:** CHAR  
**LENGTH:** 30  
**FILE(S):** Clinical and staging  
**SOURCE:** Oncology Care Model Data Registry  
**VALUES:** None Selected, Not Tested, Negative, Positive. Null/missing = n/a (not breast cancer); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)  
**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. Estrogen Receptor (ER) is routinely tested for breast cancer and is necessary for staging and treatment decisions. This variable is only populated for episodes with breast cancer.

[^ Back to TOC ^]
HER2_AMPLIFICATION

LABEL: HER2 Amplification

DESCRIPTION: HER2 amplification.

SHORT NAME: HER2_AMPLIFICATION

LONG NAME: HER2_AMPLIFICATION

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: None Selected
Not Tested
Equivocal
Negative
Positive
Null/missing = n/a (not breast gastro/esophageal cancer); or not reported by OCM participant
(reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. HER2 Amplification is routinely tested for breast cancer and gastro/esophageal cancer. It is necessary for breast cancer staging and helps determine treatment decisions. This variable is only populated for episodes with breast cancer or gastro/esophageal cancer.
### HISTOLOGY

**LABEL:** Histology  
**DESCRIPTION:** Histology.  
**SHORT NAME:** HISTOLOGY  
**LONG NAME:** HISTOLOGY  
**TYPE:** CHAR  
**LENGTH:** 30  
**FILE(S):** Clinical and staging  
**SOURCE:** Oncology Care Model Data Registry  
**VALUES:**  
- Adenocarcinoma  
- Adenocarcinoma, NOS  
- Carcinoma, NOS  
- Inflammatory  
- NSCLC - Adenocarcinoma  
- NSCLC - Large Cell  
- NSCLC - Squamous Cell  
- Non-small cell carcinoma  
- None Selected  
- Other  
- Small Cell Lung Cancer  
- Small cell carcinoma, NOS  
- Squamous cell carcinoma  
- Squamous cell carcinoma, NOS  
- Null/missing = n/a (not applicable for the type of cancer reported); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)  

**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. This variable is only populated for episodes with breast cancer, some types of gastro/esophageal cancer (ICD10 diagnosis codes C15.3, C15.4, C15.5, C15.8, C15.9, C16.0), and some types of lung cancer (ICD10 diagnosis codes C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C39.0, and C39.9).
**ICD10_CNCR_DGNS_CD_RPTD**

**LABEL:** ICD10 Cancer Diagnosis Code Reported by Participant

**DESCRIPTION:** ICD10 cancer diagnosis code reported by participant. The diagnosis code for the cancer type is classified using the International Classification of Diseases, 10th Revision, clinical modification (ICD-10-CM).

**SHORT NAME:** ICD10_CNCR_DGNS_CD_RPTD

**LONG NAME:** ICD10_CNCR_DGNS_CD_RPTD

**TYPE:** CHAR

**LENGTH:** 7

**FILE(S):** Clinical and Staging
          Current Clinical Status

**SOURCE:** Oncology Care Model Data Registry

**VALUES:** 3- to 7-digit alphanumeric value (without decimals)
            Ex — C50211

**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer.
INITL_DGNS_DT

LABEL: Initial Diagnosis Date

DESCRIPTION: Initial diagnosis date.

SHORT NAME: INITL_DGNS_DT

LONG NAME: INITL_DGNS_DT

TYPE: DATE

LENGTH: 8

FILE(S): Clinical and staging
Current clinical status

SOURCE: Oncology Care Model Data Registry

VALUES: Ex — 03/29/2015

COMMENT: Formatted as MMDDYY10 in SAS

^ Back to TOC ^
METASTASIS

LABEL: Metastasis Staging

DESCRIPTION: Metastasis staging.

SHORT NAME: METASTASIS

LONG NAME: METASTASIS

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: None Selected, M0, M1, M1a, M1a(0), M1a(1), M1b, M1b(0), M1b(1), M1c, M1c(0), M1c(1), M1d, M1d(0), M1d(1), cM0(i+), pM1, pM1a, pM1b, pM1c

Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. The Metastasis (M) category describes the presence of distant metastasis in sites and/or organs outside the local tumor area and regional nodes as defined by cancer site.

Metastasis reporting was required for breast cancer, female GU other than ovarian cancer, gastrointestinal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer — all diagnoses (except for C21.2 under the AJCC 8th edition)
- Bladder cancer — C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0
- Endocrine tumors — C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer — AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer — C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer — C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma — AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C86.3, and C86.6
- Small intestine/colorectal cancer — C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

^ Back to TOC ^
**NODAL_DISEASE**

**LABEL:** Nodal Disease Staging

**DESCRIPTION:** Nodal disease staging.

**SHORT NAME:** NODAL_DISEASE

**LONG NAME:** NODAL_DISEASE

**TYPE:** CHAR

**LENGTH:** 30

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:** None Selected, N0, N0(i+), N0a, N0b, N1, N1a, N1b, N1c, N1mi, N2, N2a, N2b, N2c, N2mi, N3, N3a, N3b, N3c, NX, pN0, pN0(i+), pN0(i-), pN0(mol+), pN0(mol-), pN1, pN1a, pN1b, pN1c, pN1mi, pN2, pN2a,
pN2b, pN2c, pN3, pN3a, pN3b, pN3c, pNX
Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. Nodal Disease (N) category describes the regional lymph node involvement as defined for each cancer site. It may include the absence or presence of cancer in regional nodes and/or the number of positive nodes, size, or involvement.

Nodal disease reporting was required for breast cancer, female GU other than ovarian cancer, gastro-esophageal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer – all diagnoses (except for C21.2 under the AJCC 8th edition)
- Bladder cancer – C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0
- Endocrine tumors – C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer – AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer – C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer – C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma – AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, and C86.6
- Small intestine/colorectal cancer – C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

[^ Back to TOC ^]
**OCM_PRCTC_ID**

**LABEL:** OCM-Assigned Practice ID

**DESCRIPTION:** OCM-assigned practice ID

**SHORT NAME:** OCM_PRCTC_ID

**LONG NAME:** OCM_PRCTC_ID

**TYPE:** CHAR

**LENGTH:** 7

**FILE(S):** Clinical and staging

**SOURCE:** CMS Oncology Care Model data

**VALUES:** Ex — OCM-123

**COMMENT:** Formatted as OCM-###

^ Back to TOC ^
**PRFMNC_PRD**

**LABEL:** OCM 6 Month Performance Period

**DESCRIPTION:** OCM six-month performance period. Episodes of care were organized by performance periods, which are the six-month periods of time during which a cohort of episodes terminated and was reconciled together.

**SHORT NAME:** PRFMNC_PRD

**LONG NAME:** PRFMNC_PRD

**TYPE:** NUM

**LENGTH:** 3

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:**

3 = Episodes beginning July 2, 2017–January 1, 2018
4 = Episodes beginning January 2, 2018–July 1, 2018
5 = Episodes beginning July 2, 2018–January 1, 2019
6 = Episodes beginning January 2, 2019–July 1, 2019
7 = Episodes beginning July 2, 2019–January 1, 2020
8 = Episodes beginning January 2, 2020–July 1, 2020
9 = Episodes beginning July 2, 2020–January 1, 2021
10 = Episodes beginning January 2, 2021–July 1, 2021
11 = Episodes beginning July 2, 2021–December 31, 2021

**COMMENT:** In OCM, episodes are initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim. Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months. Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode. Data reported for the first two OCM performance periods have not been shared because obstacles were encountered that made the data reported questionable in accuracy and reliability.

[^Back to TOC^]
**PRMRY_TUMOR**

**LABEL:** Primary Tumor Staging

**DESCRIPTION:** Primary tumor staging.

**SHORT NAME:** PRMRY_TUMOR

**LONG NAME:** PRMRY_TUMOR

**TYPE:** CHAR

**LENGTH:** 30

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:** Multiple Primaries, None Selected, T0, T1, T1a, T1a1, T1a2, T1b, T1b1, T1b2, T1c, T1c1, T1c2, T1c3, T1d, T1mi, T2, T2a, T2a1, T2a2, T2b, T2c, T3, T3a, T3b, T3c, T3d, T4, T4a, T4b, T4c, T4d,
TX, Ta, Tis, Tis (DCIS), Tis (LCIS), Tis (Paget's), Tis (Paget), pT0, pT1, pT1a, pT1b, pT1c, pT1mi, pT2, pT2a, pT2b, pT2c, pT3, pT3a, pT3b, pT4, pT4a, pT4b, pT4c, pT4d, pTX, pTa, pTis, pTis (DCIS), pTis (LCIS), pTis (Paget's), pTis (Paget)

Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. Primary Tumor (T) describes the size and/or the extension of the primary tumor specifically defined for each cancer site. Generally, the higher the Primary Tumor category (value), the greater the extent of the disease and generally the worse the prognosis; some exceptions exist.

Primary tumor reporting was required for breast cancer, female GU other than ovarian cancer, gastro-esophageal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer – all diagnoses (except for C21.2 under the AJCC 8th edition)
- Bladder cancer – C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0
- Endocrine tumors – C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer – AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer – C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer – C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma – AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C86.3, and C86.6
- Small intestine/Colorectal cancer – C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

^ Back to TOC ^
**PROGESTERONE_RECEPTOR**

**LABEL:** Breast Cancer Progesterone Receptor  
**DESCRIPTION:** Breast cancer progesterone receptor.  
**SHORT NAME:** PROGESTERONE_RECEPTOR  
**LONG NAME:** PROGESTERONE_RECEPTOR  
**TYPE:** CHAR  
**LENGTH:** 30  
**FILE(S):** Clinical and staging  
**SOURCE:** Oncology Care Model Data Registry  
**VALUES:** None Selected  
Not Tested  
Negative  
Positive  
Null/missing = n/a (not breast cancer); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)  
**COMMENT:** Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. Progesterone Receptor (PR) is routinely tested for breast cancer and is necessary for staging and treatment decisions. This variable is only populated for episodes with breast cancer.

[^ Back to TOC ^]
**RPTD_TO_RGSTRY**

**LABEL:** Participant Reported Episode to OCM Registry

**DESCRIPTION:** Indicates whether the OCM participant reported data on this episode to the OCM registry.

**SHORT NAME:** RPTD_TO_RGSTRY

**LONG NAME:** RPTD_TO_RGSTRY

**TYPE:** NUM

**LENGTH:** 3

**FILE(S):** Clinical and staging

**SOURCE:** Oncology Care Model Data Registry

**VALUES:**
- 0 = No
- 1 = Yes

**COMMENT:**

OCM participants submitted staging and clinical data to the OCM Data Registry (OCMR), a web-based data submission and collection tool, for episodes that were attributed to their practice.

Beneficiaries not reported to the OCMR (RPTD_TO_RGSTRY=0) have blank values for the following variables in the Clinical and Staging file: AJCC_EDITION, CNCR_TYPE_RPTD, ESTROGEN_RECEPTOR, HER2_AMPLIFICATION, HISTOLOGY, ICD10_CNCR_DGNS_CD_RPTD, INITL_DGNS_DT, METASTASIS, NODAL_DISEASE, PRMRY_TUMOR, and PROGESTERONE_RECEPTOR. Such beneficiaries will also not have records in the current clinical status file.

A second group of beneficiaries also has blank values for the variables listed above, those where RPTD_TO_RGSTRY = 1 but whose reported values were determined to be invalid for one of the following reasons:

1. Participant-reported cancer type (CNCR_TYPE_RPTD) not equal to OCM-assigned cancer type (CNCR_TYPE_ASGNED)
2. Practice reporting the data was not the same as the practice to which the beneficiary’s episode was attributed
3. Not all information was completely reported, or,
4. Multiple records with conflicting values for the primary tumor, nodal disease, and/or metastasis elements were reported (and it was not known which were correct).

In the first five performance periods, if a practice did not report to the OCMR, they were ineligible to be considered for a performance-based payment (reporting was required for at least 75% of episodes). For the 6th through 11th performance periods, practices were permitted to opt out of reporting due to external burdens associated with the COVID19 PHE, and were still eligible to receive performance-based payments.
**SEX**

**LABEL:** Beneficiary Sex

**DESCRIPTION:** Beneficiary sex.

**SHORT NAME:** SEX

**LONG NAME:** SEX

**TYPE:** NUM

**LENGTH:** 3

**FILE(S):** Clinical and staging

**SOURCE:** CCW Master Beneficiary Summary File (MBSF)

**VALUES:**
1 = Male
2 = Female

**COMMENT:** The CMS Oncology Care Model team obtained this information from the MBSF.